Evaluating short-term antiplatelet therapy after heart procedure for atrial fibrillation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study assesses the safety and effectiveness of a short-term single antiplatelet therapy (SAPT) regimen in patients with nonvalvular atrial fibrillation who have undergone a successful left atrial appendage closure (LAAC) procedure using the LAmbre device. It includes patients with a CHA2DS2-VASc score indicating a higher risk of stroke but who cannot take long-term anticoagulants. Participants will receive either acetylsalicylic acid or clopidogrel for three months and will be followed for 12 months to evaluate the occurrence of stroke and thromboembolic events. The study aims to provide insights into the management of patients at risk for stroke post-LAAC.

Why it matters

Who can join: the full rules

Inclusion Criteria:

All criteria must be met

* Patient 18 years and over and
* Patient with documented nonvalvular AF, defined as AF in the absence of moderate or severe mitral stenosis or a mechanical heart valve and
* Patient with a calculated CHA₂DS₂-VASc score ≥2 (for men) and ≥3 (for women) and
* Patient with a contraindication for long-term anticoagulant treatment and
* Patient who has undergone a successful LAmbre LAAC device implantation with no complications during the in-hospital period after the intervention and
* Patient able and willing to return for required follow-up visits and examinations and
* Patient with Informed consent signed.

Exclusion Criteria:

No exclusion criteria must be met.

* Patient is currently enrolled in another investigational study, except when the subject is participating in a purely observational registry with no associated treatments.
* Patient requires long-term anticoagulation therapy for reasons other than AFrelated stroke risk reduction, for example, due to an underlying hypercoagulable state (i.e even if the device is implanted, the subjects would not be eligible to discontinue OAC (Oral Anticoagulation) due to other medical conditions requiring chronic OAC therapy).
* Patient has contraindications or is allergic to both aspirin and clopidogrel.
* Patient has an indication for chronic aspirin or clopidogrel treatment (i.e., chronic ischemic disease or peripheral artery disease); thus, the subject would not be eligible to discontinue aspirin or clopidogrel due to other medical conditions requiring this therapy.
* Patient had or is planning to have any cardiac or noncardiac intervention or surgical procedure within 30 days before or 60 days after implant (including, but not limited to: cardioversion, PCI (Percutaneous Coronary Intervention), cardiac ablation, cataract surgery, etc.).
* Patient had a prior stroke (of any cause, whether ischemic or hemorrhagic) or transient ischemic attack (TIA) within the 30 days prior to enrollment.
* Patient had a major bleeding event within the 30 days prior to inclusion. Lack of resolution of related clinical sequelae or planned and pending interventions to resolve bleeding/bleeding source are further exclusions, regardless of the timing of the bleeding event.
* Patient has an active bleeding.
* Patient has had an MI documented in the clinical record as either a NSTEMI or STEMI, with or without intervention, within 30 days prior to enrollment.
* Patient has a history of atrial septal repair or has an ASD/PFO device.
* Patient is of childbearing potential, or plans to become pregnant during the study (method of assessment upon study physician's discretion).
* Patient had subject has a documented life expectancy of less than one year.

Where it's running

• Hospital Universitario A Coruña
  A Coruña, Spain Recruiting
• Hospital Clínico San Carlos
  Aravaca, Spain Recruiting
• Hospital Del Mar
  Barcelona, Spain Recruiting
• Hospital de la Santa Creu i Sant Pau
  Barcelona, Spain Recruiting
• Hospital Universitari Vall D'Hebron
  Barcelona, Spain Recruiting
• Hospital Clinic de Barcelona
  Barcelona, Spain Recruiting

Study contacts

• Study coordinator: BEATRIZ VAQUERIZO, MD, PhD
• Email: bvaquerizo@psmar.cat
• Phone: 0034987876135

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals

  This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.

  Recruiting at 2 sites Hospital Universitari Vall d'Hebron Research Institute · Leuven and 6 other locations · NCT07924371

• Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities

  This study tests how comorbid conditions like sleep apnea and primary aldosteronism relate to left-atrial fibrosis and AF recurrence in patients undergoing ablation.

  Recruiting University Hospital Augsburg · Augsburg, Bavaria · NCT07857044

• Dual Energy ablation with SmartTouch SF catheter in persistent atrial fibrillation

  This study tests a pulsed field and radiofrequency ablation system to treat persistent atrial fibrillation in adults who have not responded well to prior medications.

  Recruiting at 4 sites Biosense Webster, Inc. · Beijing and 3 other locations · NCT07845682

• Identifying AF patients who may need more than standard ablation using Volta AF-Xplorer II

  This trial tests whether AI-identified dispersion areas during AF ablation can predict recurrence after a standard pulmonary vein isolation in patients with persistent AF.

  Recruiting Volta Medical · Avignon and 4 other locations · NCT07807423

• 4D intracardiac echocardiography to guide left atrial appendage occlusion procedures

  A new 4D ICE catheter is being tested alongside standard imaging to see if it can safely guide left atrial appendage occlusion procedures for adults with atrial fibrillation.

  Recruiting The Cleveland Clinic · Cleveland, Ohio · NCT07806890

• Thoracoscopic vs Catheter Ablation as the First Rhythm Control in Atrial Fibrillation with a Large Left Atrium

  This trial tests whether thoracoscopic surgical ablation is better at keeping atrial fibrillation under control than catheter ablation in people with persistent AF and a large left atrium who have not had an ablation before.

  Recruiting Samsung Medical Center · Seoul, Seoul · NCT07783984

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.